FILSPARI

Apr 20, 2026

For decades, patients with focal segmental glomerulosclerosis had no approved treatment. Then Travere Therapeutics did the unthinkable: it turned a Phase 3 setback into a historic approval. Imagine being diagnosed with a progressive kidney disease, one that scars your kidneys from the inside, strips proteins fro...

Jun 20, 2025

IgA Nephropathy (IgAN): Pathogenesis and the Need for Targeted Therapies IgA nephropathy is a complex autoimmune disorder characterized by the accumulation of galactose-deficient IgA1 antibodies in the glomeruli, triggering a cascade of immune responses that ultimately lead to chronic kidney damage. Driven by a ...

Sep 16, 2024

A year after failing to meet a trial endpoint, Travere Therapeutics can now relax. On 05 September 2024, the FDA upgraded FILSPARI’s conditional approval for the kidney disease IgA nephropathy to full approval. FILSPARI’s complete approval broadens its use, permitting the small molecule blocker to help slow kidn...